ICOS Capital

ICOS structures each investment alongside one or more corporate strategic partners that commit engineering resources, production capacity, and market access in addition to co-investment capital. The firm acts as the hub: sourcing deals, conducting diligence, structuring the syndicate, and managing the portfolio. Corporate partners get early visibility into breakthrough technologies relevant to their industrial roadmaps; ICOS ensures the startup receives more than just a check. This is distinct from standard corporate venture capital because ICOS remains an independent fund manager negotiating terms, not a captive arm of any single industrial.

ICOS targets hard-science decarbonization: advanced materials, industrial biotechnology, circular-economy feedstocks, and process electrification — sectors where pilot facilities and first-of-a-kind plants determine success. The firm explicitly avoids consumer-facing climate apps, carbon-accounting software, and mobility pure-plays. Eligibility tests include whether the technology can realistically avoid one gigaton of CO2 equivalent emissions by 2050 if widely deployed, and whether a corporate partner's engineering or manufacturing infrastructure is essential to scaling it.

Managing Partners Nityen Lal and Peter van Gelderen lead the investment committee. Lal, who holds a PhD in chemistry, brings the technical screening lens that distinguishes ICOS from generalist venture firms; van Gelderen contributes institutional fund-management and LP-relations experience. The lean structure means the partners are directly involved in both deal origination and portfolio-company board work, with no intermediary investment-professional layer between them and founders.

ICOS Capital invests directly into companies, not into other funds. The collaborative venturing model requires direct equity stakes so the firm can structure corporate co-development rights and board-level engagement. ICOS does not operate as a fund of funds or offer LP commitments to third-party managers. Its own funding comes from institutional LPs and the corporate partners that participate in individual syndicates.

Deal flow originates significantly from the firm's network of industrial corporate partners, who identify deep-tech university spinouts, pilot-stage demonstration projects, and engineering-team carveouts that lack venture visibility. ICOS also draws on European public-research consortia and sustainability-focused accelerators. This sourcing aperture — industrial R&D pipelines rather than founder networks or VC syndicates — produces a pipeline tilted toward companies with validated business-to-business traction but limited traditional venture coverage.

ICOS invests from seed through growth equity but concentrates capital where a company has moved beyond lab-scale proof and needs industrial validation: typically a functioning pilot plant, initial offtake agreements, and the engineering team to design commercial-scale facilities. The firm rarely writes discovery-round checks into unvalidated science projects, and does not pursue buyout or pre-IPO late-stage rounds that require generalist growth-equity scale.

ICOS targets exits through strategic acquisition by industrial partners — often the same corporates already engaged as co-development collaborators — rather than public listings. The firm's design anticipates 7-to-10-year holding periods commensurate with industrial scaling timelines. Trade sales to chemicals conglomerates, materials producers, or energy-transition infrastructure owners represent the most probable realization path, a logic driven by the technology-intensive nature of the holdings.